Results 181 to 190 of about 149,399 (260)

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

Advanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen, Zhao‐Yu Liu, Gao‐Wen Qu, Run‐Hao Zeng, Wen‐Xia Yao, Yong‐Bing Zhou, Xue Liang, Yu‐Xiong Lai   +7 more
wiley   +1 more source

Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. [PDF]

Nat Biomed Eng
Huang F, Yuan F, Li K, Cui Y, Li L, Ye W, Cui Z, Yan J, Chen Q, Nicchitta C, Zhang Y, Hankey W, Everitt J, Huang KL, Wang ME, Chen M, Huang J, Wang H, Wagner EJ, Lu X, Dong Y, Li W, Wang Q.   +22 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies. [PDF]

Mol Cancer
Shichkin VP, Morva A, Ulaganathan VK, Erin N, Nativi C, Brezar SK, Rani S.   +6 more
europepmc   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

Advanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang, Peipei Song, Xueji Wu, Lei Wang, Wei Xie, Pinning Feng, Chao Cheng, Jianping Guo   +7 more
wiley   +1 more source

Immune evasion, dysregulation, and emerging immunotherapies for invasive fungal infections in the immunocompromised host. [PDF]

Front Immunol
Liu H, Wang C, Huang W, Hu S, Huang C.
europepmc   +1 more source

Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC

Advanced Science, EarlyView.
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang, Lin Ding, Yu Zhong, Haokang Feng, Linglong Huang, Waidong Huang, Chunqing Wang, Arne Östman, Beili Wang, Jian Zhou, Jia Fan, Wei Guo, Liang Wu, Yunfan Sun   +13 more
wiley   +1 more source